Table 3.
Physiological end points by treatment group
| Outcome | PMX-HP group | Non-PMX-HP group | ||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (n = 29) | Day 3 (n = 26) | P value within groupa | Baseline (n = 30) | Day 3 (n = 20) | P value within groupb | P value between groups on day 3c | P value between group change from baseline and day 3d | |
| Primary outcome | ||||||||
| mHLA-DR expression (%), median (Q1, Q3) | 33.4 (27.4–40.7) | 39.2 (27.1–45.8) | 0.025 e | 30 (15.8–36.6) | 30.7 (19.5–36.8) | 0.13 | 0.027 (0.042) e | 0.027 (0.11)e |
| mHLA-DR expression (MFI), mean (SD) | 481.4 (131.5) | 509.0 (139.9) | 0.78 | 446.6 (142.1) | 447.3 (148.9) | 0.35 | 0.16 (0.035)e | 0.34 (0.038)e |
| Secondary outcomes | ||||||||
| CD11b (%), mean (SD) | 15.4 (9) | 13.7 (9.5) | 0.30 | 14.3 (10.5) | 16.2 (10.1) | 0.001 | 0.39 (0.15)e | 0.002 (0.001) e |
| CD-11b (MFI), mean (SD) | 189.7 (57.1) | 165.4 (53.1) | 0.045 | 186.2 (53.3) | 223.5 (48.0) | < 0.001 | 0.001 (< 0.001) e | < 0.001 (< 0.001) e |
| Neutrophil chemotaxis (%), mean (SD) | 42.8 (12.5) | 47.9 (10.2) | 0.030 | 42.3 (13.7) | 46.2 (12.3) | 0.74 | 0.60 (0.77)e | 0.07 (0.08)e |
| Presepsin (pg/ml), median (Q1, Q3) | 5514 (4088, 10,513) | 2895 (2190, 6038) | 0.059 | 5030 (2459, 10,734) | 3468 (2204, 6038) | 0.12 | 0.93 | 0.38 |
| CVS SOFA score, median (Q1, Q3) | 4 (4, 4) | 3 (0, 4) | 0.003 | 4 (4, 4) | 3 (1, 4) | 0.26 | 0.71 | 0.16 |
| Inotropic score, median (Q1, Q3) | 36 (6.6, 70) | 11 (1, 49.2) | 0.13 | 30 (2, 83) | 14 (0, 36) | 0.94 | 0.57 | 0.20 |
| Vasopressor dependency index (mmHg−1), median (Q1, Q3) | 0.4 (0.1, 1.1) | 0.1 (0.01, 0.7) | 0.14 | 0.4 (0.1, 1.1) | 0.2 (0, 0.6) | 0.96 | 0.60 | 0.25 |
| Noradrenaline (μg/kg/min), median (Q1, Q3) | 0.2 (0.0, 0.4) | 0.01 (0, 0.2) | 0.23 | 0.3 (0.0, 0.4) | 0.1 (0, 0.4) | 0.85 | 0.42 | 0.42 |
| EAA level, median (Q1, Q3) | 0.8 (0.7, 1) | 0.7 (0.6, 0.9) | 0.11 | 0.7 (0.7, 0.9) | 0.6 (0.5, 0.9) | 0.14 | 0.84 | 0.90 |
Data represent median (25th percentile, 75th percentile) unless otherwise noted
PMX-HP polymyxin B hemoperfusion, mHLA-DR monocyte human leukocyte antigen, Q1 25th percentile, Q3 75th percentile, MFI mean fluorescence intensity, SD standard deviation, CVS SOFA cardiovascular Sequential Organ Failure Assessment, EAA endotoxin activity assay, Italic data represent P value statistically significant
aP value for comparison between day 1 and day 3 within PMX-HP group using Student’s t test or Kruskal–Wallis test
bP value for comparison between day 1 and day 3 within non-PMX-HP group using Student’s t test or Kruskal–Wallis test
cP value for comparison between PMX-HP and non-PMX-HP groups on day 3 using Student’s t test or Kruskal–Wallis test
dP value for comparing groups on mean or median change between day 3 and day 1 using Student’s t test or Kruskal–Wallis test
eAdjusted for renal replacement therapy status